Tag Archives: Fresenius advances Growth Vectors strategy after stronger earnings and hospital performance in Q3 2026

Fresenius increases 2026 Core EPS outlook after strong Q3 performance and growth in Kabi and Helios

Exterior of Fresenius headquarters in Bad Homburg, Germany, with entrance and company signage.

Group revenue reaches €5.8 billion as EBIT rises 10% at constant currency, with Biopharma growth and expanded biosimilars plans supporting the strategy. IN BRIEFKEY TAKEAWAYSFAQs Fresenius reported third-quarter 2026 revenue of €5,803 million, with organic growth of 5%, while Group … Read the full press release →